Artiva Biotherapeutics ARTV
NASDAQ ARTV
$7.03 -0.02 (-0.28%)
At close: Sep 29, 2026 · 4:00 PM EDT

Artiva Biotherapeutics (ARTV) EBIT Margin (2023 - 2024)

Updated

Artiva Biotherapeutics' EBIT Margin was -26805.58% in FY2024, down 26714.00 percentage points from -91.58% in FY2023.

Analysis

Artiva Biotherapeutics (ARTV) EBIT Margin (2023 - 2024) Analysis & Trends

  • Per Business Quant data, EBIT Margin in earlier years was -91.58% in FY2023.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBIT Margin (Qtr)
1 Johnson & Johnson 655.56 Bn 574.09 Bn 17.26 Bn 28.21%
2 AbbVie 470.94 Bn 444.10 Bn 12.70 Bn 37.86%
3 Merck 367.14 Bn 321.57 Bn 12.21 Bn -3.52%
4 Novartis Ag 280.33 Bn 236.20 Bn 11.24 Bn 32.97%
5 Astrazeneca 257.78 Bn 231.34 Bn 12.86 Bn 20.57%
6 Amgen 226.04 Bn 181.44 Bn 7.24 Bn 34.95%
7 Gilead Sciences 188.89 Bn 163.01 Bn 6.22 Bn -133.21%
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn 28.37%
9 Vertex Pharmaceuticals 133.68 Bn 105.69 Bn 2.84 Bn 37.40%
10 Artiva Biotherapeutics 277.86 Mn 277.86 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2024 -5,773.71%
Dec 31, 2023 -509.36%
Sep 30, 2023 40.56%
Jun 30, 2023 -338.12%
API Access

Artiva Biotherapeutics EBIT Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebit-margin&ticker=ARTV&period=max&api_key=YOUR_API_KEY